Aino Launonen

460 total citations
23 papers, 310 citations indexed

About

Aino Launonen is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Aino Launonen has authored 23 papers receiving a total of 310 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 14 papers in Oncology and 8 papers in Genetics. Recurrent topics in Aino Launonen's work include Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Viral-associated cancers and disorders (7 papers). Aino Launonen is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Viral-associated cancers and disorders (7 papers). Aino Launonen collaborates with scholars based in Switzerland, United Kingdom and United States. Aino Launonen's co-authors include Kimmo Jaakkola, Tiina Backman, Ilkka Rauramo, Pirjo Inki, Markku Koskenvuo, Tina Nielsen, Robert Marcus, Wolfgang Hiddemann, Michael Herold and John F. Seymour and has published in prestigious journals such as Blood, Obstetrics and Gynecology and Bone.

In The Last Decade

Aino Launonen

20 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aino Launonen Switzerland	8	173	159	75	72	54	23	310
Luca Giuseppe Sgrò Italy	11	145 0.8×	131 0.8×	38 0.5×	22 0.3×	9 0.2×	31	447
Hiltrud Nisters-Backes Germany	6	94 0.5×	142 0.9×	98 1.3×	121 1.7×	28 0.5×	7	298
Dagmara Klasa-Mazurkiewicz Poland	8	65 0.4×	21 0.1×	62 0.8×	34 0.5×	7 0.1×	34	250
A. H. J. T. Vriends Netherlands	15	137 0.8×	82 0.5×	16 0.2×	18 0.3×	29 0.5×	18	662
Birgit Carly Belgium	9	251 1.5×	65 0.4×	16 0.2×	17 0.2×	5 0.1×	26	396
D. G. Crüger Denmark	12	137 0.8×	97 0.6×	141 1.9×	94 1.3×	9 0.2×	17	563
Amal Yussuf United States	11	95 0.5×	90 0.6×	13 0.2×	15 0.2×	12 0.2×	29	322
E S Mayall United Kingdom	4	174 1.0×	92 0.6×	18 0.2×	11 0.2×	19 0.4×	6	497
Daniel Herr Germany	9	134 0.8×	58 0.4×	68 0.9×	20 0.3×	5 0.1×	14	330
Darryl Nousome United States	9	47 0.3×	57 0.4×	21 0.3×	43 0.6×	28 0.5×	25	286

Countries citing papers authored by Aino Launonen

Since Specialization

Citations

This map shows the geographic impact of Aino Launonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aino Launonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aino Launonen more than expected).

Fields of papers citing papers by Aino Launonen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aino Launonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aino Launonen. The network helps show where Aino Launonen may publish in the future.

Co-authorship network of co-authors of Aino Launonen

This figure shows the co-authorship network connecting the top 25 collaborators of Aino Launonen. A scholar is included among the top collaborators of Aino Launonen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aino Launonen. Aino Launonen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Herbaux, Charles, Sascha Dietrich, Andrew McMillan, et al.. (2023). Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX. Hematological Oncology. 41(S2). 432–433. 1 indexed citations

Launonen, Aino, et al.. (2023). Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study. Journal of Medical Economics. 26(1). 1178–1189. 1 indexed citations

Matasar, Matthew J., Anthony Masaquel, Aino Launonen, et al.. (2023). US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. Journal of Medical Economics. 26(1). 1134–1144. 4 indexed citations

Casulo, Carla, Michael Herold, Wolfgang Hiddemann, et al.. (2022). Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. Clinical Lymphoma Myeloma & Leukemia. 23(1). 40–48. 14 indexed citations

Tilly, Hervé, Georg Lenz, Graham P. Collins, et al.. (2022). Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study. Blood. 140(Supplement 1). 6645–6647. 1 indexed citations

Casulo, Carla, et al.. (2021). Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies. Oncology and Therapy. 9(2). 329–346. 7 indexed citations

Bachy, Emmanuel, et al.. (2021). Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. Advances in Therapy. 38(7). 3489–3505. 4 indexed citations

Spencer, Scott, Gregory F. Guzauskas, Federico Felizzi, et al.. (2021). Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma. Journal of Managed Care & Specialty Pharmacy. 27(5). 615–624. 1 indexed citations

Ayad, Sabry, et al.. (2020). PCN92 Cost Effectiveness of Obinutuzumab PLUS Chemotherapy Followed By Obinutuzumab Maintenance for Patient with Previously Untreated Advanced-STAGE Follicular Lymphoma in French Setting. Value in Health. 23. S438–S438.

10.

Hofmann, Sarah, et al.. (2020). The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany. Journal of Comparative Effectiveness Research. 9(14). 1017–1026. 2 indexed citations

11.

Launonen, Aino, et al.. (2019). PCN104 OBINUTUZUMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: AN IMPORTANT CLINICAL AND COST-EFFECTIVE OPTION FOR HIGH-RISK (INTERMEDIATE/HIGH FLIPI) PATIENTS IN CANADA. Value in Health. 22. S75–S75.

12.

Casulo, Carla, Michael Herold, Wolfgang Hiddemann, et al.. (2019). Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study. Blood. 134(Supplement_1). 5268–5268. 2 indexed citations

13.

Launonen, Aino, et al.. (2019). CLINICAL OUTCOMES OF PATIENTS WITH INTERMEDIATE‐TO‐HIGH‐RISK FOLLICULAR LYMPHOMA (FL) IN THE GALLIUM PHASE III STUDY. Hematological Oncology. 37(S2). 386–387. 1 indexed citations

14.

Seymour, John F., Robert Marcus, Andrew Davies, et al.. (2018). Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 104(6). 1202–1208. 69 indexed citations

15.

Sehn, Laurie H., Angela Giovanna Congiu, Dominic Culligan, et al.. (2018). No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study. Blood. 132(Supplement 1). 783–783. 18 indexed citations

16.

Mir, Farheen, Andrew Grigg, Michael Herold, et al.. (2018). A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial. Blood. 132(Supplement 1). 2872–2872. 3 indexed citations

17.

Launonen, Aino, et al.. (2017). Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study. Blood. 130. 1490–1490. 12 indexed citations

18.

Cheson, Bruce D., Peter C. Trask, John G. Gribben, et al.. (2016). Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Annals of Hematology. 96(2). 253–259. 18 indexed citations

19.

Mindeholm, Linda, Aino Launonen, Beate Kiese, et al.. (2012). The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone. 50(4). 965–973. 37 indexed citations

20.

Backman, Tiina, Ilkka Rauramo, Kimmo Jaakkola, et al.. (2005). Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer. Obstetrics and Gynecology. 106(4). 813–817. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact